AbbVie

AbbVie is a global biopharmaceutical company that discovers, develops, and markets a range of prescription medicines. Its portfolio includes treatments for immunology, oncology, neuroscience, eye care, and virology. The company’s best‑known product is Humira (adalimumab), which has been used worldwide for autoimmune conditions. AbbVie serves patients and healthcare providers in numerous countries across North America, Europe, Asia, and other regions.

The company maintains a substantial research and development organization that invests heavily in discovering new therapies. AbbVie operates manufacturing and commercial sites in multiple countries to support its global supply chain. It is listed on the New York Stock Exchange under the ticker ABBV and is included in major market indices. AbbVie employs a large workforce that works in research, clinical development, manufacturing, and commercial functions.

AbbVie distinguishes itself through a strong focus on immunology and oncology, areas where it has generated several blockbuster drugs and continues to advance pipeline candidates. The company also emphasizes neuroscience and eye care, reflecting a diversified therapeutic approach. Its regulatory expertise enables it to navigate complex approval processes in the United States, Europe, and other jurisdictions. AbbVie’s commitment to innovation is evidenced by its sustained investment in early‑stage research and strategic collaborations with academic institutions and biotech firms.

Structurally, AbbVie emerged as an independent entity after being spun off from Abbott Laboratories in 2013, and it has since operated as a standalone publicly traded corporation. The company does not have a parent organization and oversees its own subsidiaries that manage specific therapeutic areas or geographic regions. This independence allows AbbVie to set its own strategic priorities while leveraging the scientific heritage inherited from its predecessor.